Archive · 25 Jul 2025
Hyderabad Startup Achieves Breakthrough in Liver Failure Therapy
A startup in Hyderabad has made a big breakthrough!
They tested a new medicine called Tulsi-28X on animals with liver problems.
This medicine uses special cells to help fix the liver.
In the trial, all animals given the medicine got better, and none died.
This is a first in the world!
The company is now planning to test the medicine on people.
The new therapy could be a big deal because it may offer a new treatment for liver failure.
Hyderabad-based startup Tulsi Therapeutics announced world's first successful animal trial of novel stem cell-exosome therapy.
The therapy, Tulsi-28X, combines Wharton’s Jelly mesenchymal stem cells and exosomes.
The preclinical trial showed 100% reversal of liver fibrosis in treated animals.
The research was conducted in collaboration with experts from the USA and India.
Human clinical trials for Tulsi-28X are planned with NIMS.
- Who
- Tulsi Therapeutics, a startup incubated at the University of Hyderabad.
- What
- Successful animal trial of stem cell-exosome therapy for chronic liver failure.
- When
- Key results were presented at AASLD 2024 and accepted for publication.
- Where
- Conducted in Hyderabad, India.
- Why
- To develop a new treatment for chronic liver failure, which currently has limited treatment options.
- Therapy Name
- Tulsi-28X
- Therapy Type
- Stem cell-exosome combination
- Trial Result
- 100% reversal of liver fibrosis in treated animals
- Next Step
- Human clinical trials
- Startup Location
- Hyderabad, India
- Global Deaths Related to Liver Failure
- Nearly 20%